KK
SYRE icon

KLP Kapitalforvaltning’s Spyre Therapeutics SYRE Stock Holding History

KLP Kapitalforvaltning’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
12,800
+1,900
+17% +$139K ﹤0.01% 1058
2026
Q1 		$550K Buy
10,900
+500
+5% +$18.9K ﹤0.01% 1384
2025
Q4 		$341K Buy
10,400
+2,600
+33% +$67.9K ﹤0.01% 1599
2025
Q3 		$131K Hold
7,800
– – ﹤0.01% 1985
2025
Q2 		$117K Hold
7,800
– – ﹤0.01% 1993
2025
Q1 		$126K Hold
7,800
– – ﹤0.01% 1934
2024
Q4 		$182K Buy
+7,800
New +$229K ﹤0.01% 1858

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

KLP Kapitalforvaltning's SYRE Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Spyre Therapeutics (SYRE) stake by 17% in Q2 2026, buying an estimated $139K and bringing the position to 12,800 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1058.

KLP Kapitalforvaltning first reported a position in SYRE in Q4 2024 and has held it in 7 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • KLP Kapitalforvaltning held 12,800 shares of Spyre Therapeutics worth $1.14M as of Q2 2026.
  • KLP Kapitalforvaltning bought 1,900 Spyre Therapeutics shares in Q2 2026, an estimated $139K.
  • Spyre Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1058 holding.
  • KLP Kapitalforvaltning first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.